Abstract: The present invention relates to a method of diagnosing GERD (gastroesophageal reflux disease) in a human subject suspected to have GERD which comprises grading the endoscopic status and the symptomatic status of the human subject with individual grading parameters, and combining said grading parameters into a single parameter. The present invention also relates to a processing device for use in the method according to the invention and a means for displaying the single parameter. Furthermore the invention is concerned with uses of active ingredients having an ameliorative effect for GERD for the preparation of a medicament for treating GERD in a human patient who has been diagnosed GERD-positive by the method of the invention. The method of the invention represents the first integrated concept of diagnosing GERD.

Abstract: Novel compositions for the treatment of IRDS and ARDS are indicated which contain a compound of formula (I), in which R1 is hydrogen or 2-(2-hydroxyethoxy)ethyl and/or a pharmacologically tolerable salt of this compound and lung surfactant

Abstract: The compounds of a certain formula (1), in which R1, R2, R3, R31, R4, R5, R6 and R7 have the meanings as given in the description, are novel effective PDE4 inhibitors.

Abstract: The invention provides compounds of the formula (I) in which the substituents and symbols are as defined in the description. The compounds inhibit the secretion of gastric acid.

Abstract: The present invention relates to a novel type of medicine pack comprising a plurality of blister units (1), said blister units (1) each having a protective case (6), with a blister strip (4) located therein, the blister strip (4) being fixedly connected to the protective case (6), and the protective case being able to be unfolded or opened out, and also, if appropriate, an outer package (5, 5a) for receiving the blister units (1).

Abstract: The invention relates to the combined administration of a pulmonary surfactant and a PDE5 inhibitor for the treatment of a disease in which pulmonary surfactant malfunction and/or phosphodiesterase 5 (PDE5) activity is detrimental.

Abstract: The invention relates to a new method of treatment of respiratory diseases, in particular the treatment of asthmatic smoking patients. The method comprises the administration of a pharmaceutical composition comprising ciclesonide.

Abstract: The invention provides compounds of the formula (I), in which the substituents and symbols are as defined in the description. The compounds inhibit the secretion of gastric acid.

Abstract: The invention relates to compounds of the formula 1, in which R1, R2, R3, Arom and PG have the meanings as indicated in the description. These compounds are valuable intermediates for the preparation of pharmaceutically active compounds.

Abstract: This invention relates to a method for the preparation of sterile aqueous suspensions of ciclesonide by sterilization with moist heat. The invention further relates to pharmaceutical compositions in particular to sterile aqueous suspensions of ciclesonide for administration by nebulization in the prophylaxis and/or treatment of respiratory diseases.

Abstract: The compounds of formula I in which the substituents have the meanings as indicated in the description, are novel effective PDE4 inhibitors.

Abstract: The invention relates to the use of a pyrrolo ‘2,1-a’ isoquinoline structure-element as an integral part of the overall structure of compounds which inhibit PDE10.

Abstract: Described is a novel process for the production of at least one protein of interest by secretion of the protein of interest from a pro- or eukaryotic host cell in a compartment system, which host cell is stably expressing a secretion system and capable of heterologous secretion of the protein of interest and which compartment system has at least a first and a second compartment and wherein the host cell is located in the first compartment and wherein the first and second compartment are separated from each other by a barrier, wherein the barrier is permeable for the secreted protein of interest, but not permeable for the host cell.

Abstract: The invention provides compounds of the formula 1, in which the substituents and symbols are as defined in the description. The compounds inhibit the secretion of gastric acid.

Abstract: Compounds of formula 1, in which the substituents have the meanings mentioned in the description are suitable for the prevention and treatment of gastrointestinal diseases.

Abstract: The compounds of formula I in which R1, R2, R3, R4 and R5 have the meanings as given in the description are PDE4/7 inhibitors.

Abstract: The invention describes the use of Tetrahydrobiopterin (BH4) or derivatives thereof for the treatment of COPD. In a preferred embodiment, BH4 or derivates thereof are combined with arginine or derivatives thereof.

Abstract: The compounds of Formula (I) in which R1, R2, R3 and R4 have the meanings as given in the description are novel effective iNOS inhibitors.

Abstract: The compounds of Formula (I) in which R1, R2, R3, R4, R5 and A have the meanings as given in the description are novel effective iNOS inhibitors.

Abstract: The compounds of formula I in which the given substituents have the meanings as given in the description, are novel effective PDE4 inhibitors.